Alpha 2.0
Login Register
» Articles » PMID: 27651909

Effect of Inhaled Corticosteroids on Blood Eosinophil Count in Steroid-naïve Patients with COPD

Overview
Journal BMJ Open Respir Res
Date 2016 Sep 22
PMID 27651909
Citations 21
Authors
James L Kreindler
Michael L Watkins
Sally Lettis
Ruth Tal-Singer
Nicholas Locantore
Affiliations
Soon will be listed here.
Abstract

Introduction: Sputum and blood eosinophil counts have attracted attention as potential biomarkers in chronic obstructive pulmonary disease (COPD). One question regarding the use of blood eosinophils as a biomarker in COPD is whether their levels are affected by the use of inhaled corticosteroids (ICS), which are commonly prescribed for COPD.

Methods: We performed a retrospective analysis of peripheral blood leucocytes from a previously completed clinical trial that examined effects of ICS in steroid-naïve patients with COPD.

Results And Conclusion: The data show that the ICS-containing treatment arms (containing fluticasone propionate) had a small effect on peripheral blood eosinophils in steroid-naïve patients with COPD.

Trial Registration Number: NCT00358358; Post-results.

Citing Articles

Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up.

Pignatti P, Visca D, Zappa M, Zampogna E, Saderi L, Sotgiu G BMC Pulm Med. 2024; 24(1):247.

PMID: 38764008 PMC: 11102620. DOI: 10.1186/s12890-024-03062-1.

Rate of severe exacerbations, healthcare resource utilisation and clinical outcomes in patients with COPD in low-income and middle-income countries: results from the EXACOS International Study.

Athanazio R, Bernal Villada L, Avdeev S, Wang H, Ramirez-Venegas A, Sivori M BMJ Open Respir Res. 2024; 11(1).

PMID: 38637115 PMC: 11029392. DOI: 10.1136/bmjresp-2023-002101.

Current Perspectives of Pharmacotherapies for COPD.

Pleasants R, Donohue J Respir Care. 2023; 68(7):927-938.

PMID: 37353337 PMC: 10289617. DOI: 10.4187/respcare.10952.

Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation.

Antus B, Barta I Biomedicines. 2022; 10(9).

PMID: 36140229 PMC: 9496115. DOI: 10.3390/biomedicines10092128.

Withdrawal of inhaled corticosteroids from patients with COPD with mild or moderate airflow limitation in primary care: a feasibility randomised trial.

Harries T, Gilworth G, Corrigan C, Murphy P, Hart N, Thomas M BMJ Open Respir Res. 2022; 9(1).

PMID: 36041773 PMC: 9438092. DOI: 10.1136/bmjresp-2022-001311.

References
1.
Keatings V, Jatakanon A, Worsdell Y, Barnes P . Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997; 155(2):542-8. DOI: 10.1164/ajrccm.155.2.9032192. View
2.
Siva R, Green R, Brightling C, Shelley M, Hargadon B, McKenna S . Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007; 29(5):906-13. DOI: 10.1183/09031936.00146306. View
3.
Brightling C, McKenna S, Hargadon B, Birring S, Green R, Siva R . Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005; 60(3):193-8. PMC: 1747331. DOI: 10.1136/thx.2004.032516. View
4.
Ortega H, Liu M, Pavord I, Brusselle G, FitzGerald J, Chetta A . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13):1198-207. DOI: 10.1056/NEJMoa1403290. View
5.
Liesker J, Bathoorn E, Postma D, Vonk J, Timens W, Kerstjens H . Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med. 2011; 105(12):1853-60. DOI: 10.1016/j.rmed.2011.07.002. View